培美曲塞联合顺铂一线治疗晚期非小细胞肺癌临床研究

目的研究培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效及不良反应。方法 52例晚期非小细胞肺癌患者,给予培美曲塞联合顺铂方案全身化疗。培美曲塞:500mg/m2,第1天静脉滴注,顺铂:75mg/m2,第1天静脉滴注,每21天为1个周期,连用2～6个周期。结果 52例患者中非鳞癌41例,鳞癌11例,完全缓解(CR)1例,部分缓解(PR)18例,稳定(SD)13例,进展(PD)20例,总有效率(CR+PR)为36.5%,疾病控制率(CR+PR+SD)为61.5%;不同年龄、性别、临床分期、病理类型之间在有效率和疾病控制率方面差异无统计学意义(P>0.05)。所有患者PFS为4.8个月,非鳞癌患者为5.1个月,鳞癌患者为4.4个月,但两者之间差异无统计学意义(P>0.05);不良反应主要是消化道反应和骨髓抑制,多为Ⅰ～Ⅱ级。结论培美曲塞联合联合顺铂是一线治疗晚期非小细胞肺癌安全、有效的治疗方案。

Clinical Study of Pemetrexed plus Cisplatin Compounds as First-line Chemotherapy on Advanced Non-small-cell Lung Cancer

Objective To assess the overall response rate and toxicity of pemetrexed puls cisplatin in the patients with advanced non-small-cell lung cancer (NSCLC). Methods 52 patients with advanced NSCLC received pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 on day 1. One cycle of treatment was 21 days, and the whole treatment lasted for 2 to 6 cycles. Results Among 52 patients, 41 patients were non-squamous cell cancer, 11 patients were squamous cell carcinoma. 1 patient showed complete response, 18 cases showed partial response (PR), 13 cases showed stable disease (SD), 20 cases showed progress disease (PD); the overall response rate was 36.5%, and the disease control rate was 61.5%. There was no significant difference in overall response rate and disease control rate between the age, gender, stage and histology (P >0.05). Among the 52 patients, the median progression-free survival (PFS) was 4.8 months, there was no significant difference in PFS between the patients with and without squamous histology (5.1 months vs 4.4 months, P >0.05); the principal drug-related adverse events were gastrointestinal response and myelosuppression, most of which were grade 1 to 2. Conclusions Pemetrexed plus platinum compunds is safe and effective for the first treatment of patients with advanced NSCLC.